Bispecific antibodies can treat new coronavirus variantsBispecific antibodies can treat new coronavirus variants Bispecific antibodies can treat new coronavirus variants
Source: NatureSource: Nature Source: Nature
On March 25, a paper published in Nature showed that researchers found an antibody that can strongly neutralize SARS-CoV-2 and its variants, and protect mice from COVID-19 .
Pre-clinical trials have shown that this bispecific antibody can effectively neutralize SARS-CoV-2 and its variants, including the British variant B.
7, which has recently been circulating in Sweden and Europe with an accelerated spread.
Compared with antibodies that target only one viral site, this bispecific antibody prevents the virus from changing its structure to evade treatment.
New method: trick SARS-CoV-2 virus to avoid infecting host cellsNew method: Deception SARS-CoV-2 virus to prevent infection of host cells New method: Deception SARS-CoV-2 virus to prevent infection of host cells infected
Source: Chemical NewsletterSource: Chemical Newsletter Source: Chemical Newsletter
Recently, a paper published in Chemical Newsletter showed that researchers have newly studied a compound that may provide a basis for the development of drugs against COVID-19.
The researchers explained that SARS-CoV-2 got its name because of its unique coronal envelope that protects its RNA from damage.
This coronoid is composed of viral spike protein and can specifically interact with an enzyme called the ACE2 receptor.
The researchers found that by making the modified peptides (a small part of the protein) look like ACE2 receptors, they can be used as bait to prevent the binding of the SARS-CoV-2 spike protein.
AstraZeneca updates vaccine data, reducing effectiveness by 3%AstraZeneca updated the vaccine data, the effectiveness decreased by 3% AstraZeneca updated the vaccine data, the effectiveness decreased by 3%
On March 25, British pharmaceutical company AstraZeneca announced the latest phase III clinical trial data of its adenovirus vector vaccine AZD1222.
Data showed that the vaccine was 76% effective in preventing symptomatic new coronary pneumonia in 32,449 subjects in the United States, Peru, and Chile , which was 3% lower than the controversial data released on March 22.
There were 190 cases of symptomatic infection, an increase of 49 cases from the previous report; and the vaccine was well tolerated, and no safety issues related to the vaccine were found.
In response to key mutations of the new coronavirus, the protective effect of the vaccine is much higher than that of natural infectionIn response to key mutations of the new coronavirus, the protective effect of the vaccine is much higher than that of natural infections .
The protective effect of the vaccine is much higher than that of natural infections.
The neutralizing antibody response of the acutely infected (A), the recovered from the infection (B) and the vaccinated (C) against the 4 new coronavirus strains.
Recently, the Journal of the American Medical Association (JAMA) published an important study, the results of neutralizing antibody responses to 4 new coronavirus mutant strains showed that natural infection and vaccination can help prevent infection of 4 virus strains, but mRNA- The serum neutralization activity brought by 1273 new crown vaccination is much higher than the protection brought by previous infections.
The four new coronaviruses are A.
1 lineage (nCoV / USA_WA1 / 2020), B.
1 lineage (EHC-083E), B.
7 (SARS-CoV-2 / human / USA / CA_CDC_5574 / 2020), N501Y .
One-third of patients with new crown reported that their condition worsened after discharge, and more than half had persistent symptomsOne-third of patients with COVID-19 report that their condition worsens after discharge, and more than half have persistent symptoms.
1/3 of patients with COVID-19 report that their condition worsens after discharge, and more than half have persistent symptoms.
Source: Nature MedicineSource: Nature Medicine Source: Nature Medicine
Recently, a research paper published online by "Nature Medicine" comprehensively counted the sequelae of various new coronary pneumonia.
The study showed that dyspnea is the most common persistent symptom (42 to 66%) of patients with new coronary pneumonia; the incidence of venous thromboembolism is less than 5%; in the 60-day follow-up survey of patients with new coronary pneumonia , up to 20% of patients reported chest pain Symptoms: About 5% of patients with COVID-19 and 20-31% of patients with severe COVID-19 have severe acute kidney injury; about 20% of patients have symptoms of hair loss.
In addition, a small number of patients have symptoms of diabetic ketoacidosis, gastrointestinal and hepatobiliary sequelae, and nervous system sequelae.
Discovered that the new coronavirus protein can bind to and activate the receptor TLR4Found that the new coronavirus protein can bind and activate the receptor TLR4 Discover that the new coronavirus protein can bind and activate the receptor TLR4
Source: Cell ResearchSource: Cell Research Source: Cell Research
Recently, a research paper published by Cell Research showed that some researchers explained the innate immune phenotype of the new coronavirus from the perspective of molecular mechanism , and found that the new coronavirus coronavirus can directly bind to and activate pattern recognition receptors.
The researchers determined the affinity of trimeric corona protein with TLR4 through surface plasmon resonance, and successfully inhibited the activation of corona protein on natural immunity in cell experiments through inhibitors of key molecules of the TLR4 pathway, and applied key molecules to knock out.
Blocks the activation of natural immunity by coronavirus
The above experiments proved that blocking the TLR4 pathway can inhibit the innate immune phenotype characteristic of the new coronavirus, providing a theoretical basis and potential drug targets for the treatment of patients with new coronary pneumonia.
Quantitative assessment of exhaled aerosols is essential to slow the spread of COVID-19Quantitative assessment of exhaled aerosols is essential to slow down the spread of COVID-19 Quantitative assessment of exhaled aerosols is essential to slow the spread of COVID-19
Breath particles of 120 volunteers (A) All participants (B) "Super spreader" participants (C) "Super spreader" participants; (4) "Low spread" participants Source: PNASBreath particles of 120 volunteers (A) all participants (B) "super spreaders" participants (C) "super spreaders" participants; (4) "low spread" participants source: PNAS 120 volunteers Participants in the breath (A) all participants (B) "super spreaders" participants (C) "super spreaders" participants; (4) "low spread" participants Source: PNAS
Recently, a research paper published in the Proceedings of the National Academy of Sciences (PNAS) stated that, in the absence of an effective and widely spread vaccine, quantitative assessment and control of exhaled aerosols are essential for slowing down COVID-19 in the air.
The spread of may be crucial.
The research team observed the exhaled breath particles of 194 healthy people and studied 8 non-human primates infected with SARS-CoV-2 aerosol in the experiment: aerosol exhaled between subjects There are three orders of magnitude difference between the particles, and the number of breath droplets exhaled increases with the degree of COVID-19 infection and the number of years of BMI.
India now double mutationIndia has double mutation India has double mutation
Distribution of mutations in Spike protein region 414-583Distribution of mutations in Spike protein region 414-583 Distribution of mutations in Spike protein region 414-583
On March 24, India discovered a new variant of the new coronavirus (SARS-CoV-2) strain.
This strain has a double mutation and also has E484Q and L452R mutations.
Indian virologist Shahid Jamir explained: "Double mutations in key regions of the virus's S protein may increase these risks and allow the virus to escape the immune system.
" He added that these genetic variants may be worrying, but he disagrees with linking them to the surge.
New treatment for COVID-19 VIR-7831New treatment for COVID-19 VIR-7831 New treatment for COVID-19 VIR-7831
Recently, GlaxoSmithKline submitted a new COVID-19 therapy VIR-7831 to the FDA .
It is not a COVID-19 vaccine, but an antibody drug that directly prevents the virus from entering cells.
According to the official, this is an investigational double-acting SARS-CoV-2 monoclonal antibody.
A recently completed phase III trial looked at 583 patients.
An interim analysis found that compared with patients receiving placebo, 85% of patients received VIR-7831 in hospitalization or fewer deaths.
In addition, pre-clinical data indicates that VIR-7831 targets a highly conserved epitope of spike protein, which may make the development of virus resistance more difficult.
Leave a message here